WO2011114472A1 - ヒアルロン酸の精製方法 - Google Patents
ヒアルロン酸の精製方法 Download PDFInfo
- Publication number
- WO2011114472A1 WO2011114472A1 PCT/JP2010/054595 JP2010054595W WO2011114472A1 WO 2011114472 A1 WO2011114472 A1 WO 2011114472A1 JP 2010054595 W JP2010054595 W JP 2010054595W WO 2011114472 A1 WO2011114472 A1 WO 2011114472A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- activated carbon
- hyaluronic acid
- purification
- hyaluronic
- impurities
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
Definitions
- the present invention relates to a purification method of hyaluronic acids, a purification agent and activated carbon used in the purification method, and a production method thereof.
- Hyaluronic acid is used as a medicine in cosmetics, moisturizers, ophthalmology, orthopedics, dermatology and the like.
- Hyaluronic acid can be produced from extracts from animal tissues such as chicken crowns, vitreous bodies of cattle eyes, etc., but chondroitin sulfate etc. are mixed as contaminants, hyaluronidase contained in the tissues, etc. Therefore, it is easy to reduce the molecular weight by culturing microorganisms capable of producing hyaluronic acid, and producing hyaluronic acid from the culture solution (fermentation method) (Non-patent Document 1 and Patent Document 1).
- hyaluronic acid produced by an extraction method or fermentation method contains proteins, pyrogens, and the like as impurities
- a method for obtaining a high-purity product by separating and removing these has been studied.
- the removal of impurities in the initial stage of production is expected to be developed as a method for obtaining a high-purity product that can be used as a pharmaceutical because it can reduce the load of the subsequent purification process.
- exothermic substances, proteins, and the like are removed from the fermentation broth using, for example, a purification method in which hyaluronic acid is precipitated and separated from impurities by adding an organic solvent such as alcohol to the fermentation broth, or an anion exchange resin.
- a method for purifying hyaluronic acid is disclosed (Patent Document 2).
- the present invention has been made in view of the above circumstances, and an object of the present invention is to provide a method for purifying hyaluronic acids with high purity and purity on an industrial scale. It is another object of the present invention to provide a purification agent, activated carbon, etc. used in the purification method and a method for producing them.
- the present inventors have conducted various studies on methods for efficiently separating and removing impurities from a hyaluronic acid-containing liquid and purifying high-purity hyaluronic acid simply and efficiently. It has been found that impurities can be efficiently adsorbed and removed by using activated carbon prepared using a treatment method, and the present invention has been completed.
- a method for purifying hyaluronic acid and / or a salt thereof comprising a step of bringing a hyaluronic acid and / or a salt thereof and a hyaluronic acid solution containing impurities into contact with an activated carbon suspension.
- impurities can be efficiently adsorbed and removed by using activated carbon.
- the step of suspending activated carbon in an aqueous liquid to obtain an activated carbon suspension the step of heating the activated carbon suspension at 100 ° C. or higher for 20 minutes or more, and the activated carbon suspension after the heating.
- a method for purifying hyaluronic acid comprising a step of stirring and cooling a suspension, and a step of bringing a hyaluronic acid solution containing hyaluronic acid and impurities into contact with an activated carbon suspension after stirring and cooling.
- impurities can be efficiently adsorbed and removed by using activated carbon pretreated in a state suitable for purification of hyaluronic acids.
- the step of suspending activated carbon in an aqueous liquid to obtain an activated carbon suspension the step of heating the activated carbon suspension at 100 ° C. or more for 20 minutes or more, and the activated carbon suspension after the heating.
- a method for producing a purification agent for hyaluronic acid comprising the step of stirring and cooling the suspension. According to this production method, a purification agent for hyaluronic acid capable of efficiently adsorbing and removing impurities can be produced by pretreating activated carbon into a state suitable for purification of hyaluronic acid.
- the step of suspending activated carbon in an aqueous liquid to obtain an activated carbon suspension the step of heating the activated carbon suspension at 100 ° C. or more for 20 minutes or more, and the activated carbon suspension after the heating.
- a method for pretreatment of activated carbon comprising the step of stirring and cooling the suspension. According to this pretreatment method, the activated carbon can be pretreated to a state suitable for purification of hyaluronic acids.
- the step of suspending activated carbon in an aqueous liquid to obtain an activated carbon suspension the step of heating the activated carbon suspension at 100 ° C. or more for 20 minutes or more, and the activated carbon suspension after the heating.
- a purification agent for hyaluronic acid comprising activated carbon produced by a method comprising stirring and cooling a suspension.
- hyaluronic acid includes free hyaluronic acid and any hyaluronic acid salt that can be used within the range not impairing the object of the present invention (for example, but not limited to, sodium salt)
- Metal salts such as potassium salt, calcium salt and lithium salt, acid adducts such as hydrochloride, phosphate and citrate) and hydrates, and mixtures thereof.
- hyaluronic acid refers to a high molecular weight polysaccharide in which disaccharide units in which N-acetyl-D-glucosamine and D-glucuronic acid are linked are repeated, and various salts are mainly composed of glucuronic acid moieties.
- Hyaluronic acid is easy to expand into space due to the interaction between the foldable chain moiety and the negative charge of the carboxyl group of the D-glucuronic acid moiety, and can bind to a large amount of water to form a gel. Even at low concentrations, the intermolecular force is strong, so it has a relatively high viscosity. From such an action, it has, for example, a joint wetting action, a skin softening action and the like, and physiologically plays these roles.
- hyaluronic acids sodium hyaluronate with a molecular weight of about 2 million Da is more effective for treating osteoarthritis of the knee, periarthritis, rheumatoid arthritis, etc. (Pharmacology and treatment, Vol. 22, No. 9, 289 (1994); Pharmacology and treatment, Vol. 22, No. 9, 319 (1994)).
- hyaluronic acids having an average molecular weight of 1 million or more.
- hyaluronic acids having an average molecular weight of 1 million to 5 million Da are desirable as pharmaceuticals, and hyaluronic acids having an average molecular weight of 1.5 to 4 million Da are particularly desirable. Further, such high molecular weight hyaluronic acids exhibit excellent effects due to their high moisturizing power even when used as cosmetics.
- an injectable solution for dissolving hyaluronic acids as pharmaceuticals water for injection, physiological saline, etc. are generally used for injection in which pH adjusting agents including buffers such as acids, alkalis and phosphates are added.
- a solution (for example, one recognized by the pharmacopoeia of each country) can be used as appropriate.
- hyaluronic acids may be produced by an extraction method extracted from animal tissue or may be produced by a fermentation method obtained by fermentation using a hyaluronic acid-producing microbial strain.
- those extracted from animal tissues are relatively rich in impurities such as other mucopolysaccharides and have a small molecular weight, so it is desirable to use those obtained by fermentation.
- hyaluronic acids can be obtained by a known method using, for example, a Streptococcus microorganism.
- the culture solution used in the method of the present invention it is desirable to use the culture solution as it is.
- a solution sterilized by a known method such as centrifugation or filtration may be used.
- operations such as removal of low molecular weight compounds by dialysis treatment, removal of water-insoluble fine particles by microfiltration treatment, etc. may be performed, and a solution obtained by precipitating hyaluronic acid by adding a water-soluble organic solvent such as alcohol is used. May be used.
- Streptococcus in the present specification includes any bacterium belonging to the genus Streptococcus capable of producing hyaluronic acid and its mutant strain.
- Streptococcus equi FM-100 described in Patent Document 2 (Microtechnical Laboratories No. 9027) and Streptococcus ex FM-300 described in Japanese Patent Application Laid-Open No. Hei 2-23489 It is desirable to use a mutant that stably produces hyaluronic acid with a high yield such as No. 2319).
- bacteria belonging to the genus Streptococcus suitable for the production of hyaluronic acid include, but are not limited to, for example, Streptococcus equi, Streptococcus zooepidemicus, and Streptococcus zooepidemicus (Streptococcus equisimilis), Streptococcus dysgalactiee, Streptococcus pyogenes (Streptococcus pyogenes), and mutants thereof.
- average molecular weight in this specification refers to the viscosity average molecular weight when indicating the average molecular weight of hyaluronic acids.
- the viscosity average molecular weight can be determined by a method usually performed by those skilled in the art. Preferably, it can be determined by a measurement method generally used in the pharmacopoeia of each country, and more preferably by a measurement method used in the Japanese pharmacopoeia. For example, the present invention is not limited to this.
- the average molecular weight can be obtained by the following equation using the intrinsic viscosity [ ⁇ ].
- activated carbon refers to porous carbon that is commercially available and generally used for separation, removal, and purification. It is derived from raw materials such as coal or wood, activated chemicals, or water vapor. It is not limited to manufacturing methods, such as activation. Furthermore, it is not limited to shapes such as powdered activated carbon and granular activated carbon, and properties such as dry and wet. Although it is not limited to this in the method of this invention, etc., it is desirable to use activated carbon derived from wood. Similarly, it is desirable to use one produced by steam activation. Similarly, it is desirable to use powdered activated carbon.
- the activated carbon include, but are not limited to, for example, Tsurumi Coal GL-30S, Tsurumi Coal HC-30S (more granular, manufactured by Tsurumi Co.), white birch WH5C8 / 32, white birch LH2C20 / 48, white birch WH2C8 / 32SS [above, granular, manufactured by Takeda Pharmaceutical Co., Ltd.], white birch A, white birch P, purified white birch, characteristic white birch, carborafine [over, powdered, manufactured by Takeda Pharmaceutical Co., Ltd.], Hokuetsu SD, Hokuetsu GSA [above, powdered, manufactured by Hokuetsu Carbon Industry Co., Ltd.], silver A, flower F, snow A [above, powdered, manufactured by Daisan Industry Co., Ltd.], and the like.
- Tsurumi Coal GL-30S Tsurumi Coal HC-30S (more
- impurities refers to substances other than hyaluronic acids, water and other solvent components, inorganic salts, particularly substances that can give disadvantages when using hyaluronic acids as final products (such as pyrogenic substances). That means.
- main impurity sources include those derived from tissues, microorganisms, or culture solutions (medium) in the production stage of hyaluronic acids, or those mixed in subsequent purification stages.
- impurities in the present specification include, but are not limited to, tissues or cells, proteins, nucleic acids, polysaccharides, low molecular compounds, endotoxins, and the like.
- the tissue or fungus body as an impurity is not limited to this, but a tissue piece derived from a tissue as an extraction raw material used in the extraction method or the fungus body or fungus body of a microorganism used in the fermentation method, respectively. Includes pieces.
- Proteins as impurities include, but are not limited to, proteins derived from the tissues and fungi, and proteins mixed in the post-production process.
- Endotoxins as impurities include, but are not limited to, lipopolysaccharides derived from the above bacteria.
- the “low molecular weight compound” in the present specification refers to a compound having a relatively small molecular weight as compared to hyaluronic acids.
- the molecular weight is not limited to 2000 Da or less, or a molecular weight of 1000 Da, Alternatively, it refers to a compound having a molecular weight of 500 Da or less.
- Such low molecular weight compounds include various amino acids, organic acids (for example, lactic acid), sugars (for example, glucose) and the like.
- the “aqueous liquid” refers to a liquid mainly composed of water (solvent), and includes liquids containing various salts, buffers, and small amounts of organic solvents.
- any liquid can be used as long as the object of the present invention is not impaired.
- water is preferable from the viewpoint of preventing unnecessary substances from being mixed when using the hyaluronic acid as a final product.
- stirring cooling refers to cooling the target liquid by continuing stirring.
- the temperature achieved after stirring and cooling is defined as a cooling completion temperature.
- “Clean environment” in this specification refers to the production of products that are extremely unlikely to contaminate products with impurities such as bacteria and endotoxins derived from the environment, especially products that are equivalent to pharmaceuticals (bacteria and endotoxins) by air conditioning management. It refers to the environment.
- the clean environment for example, an environment in which the target substance is regulated as follows can be given.
- Removal in this specification includes not only removing the target substance completely but also removing it partially (decreasing the amount of the substance).
- purification includes removing any or specific impurities.
- purifying agent refers to an agent used for purification, such as an adsorbent
- the expression “purifier for substance A” refers to an agent for purifying substance A.
- the purification agent may be in the form of a purification composition.
- the removal agent, the separation agent, and the like refer to a drug used for removal and a drug used for separation, respectively, for example, a term including an adsorbent, a carrier, etc.
- the composition may be in the form of a composition for separation or a composition for separation.
- each numerical range in this specification includes the upper limit value and the lower limit value indicated by “to”.
- the description “A to B” means greater than A and less than B.
- “Contains” includes “consisting essentially of” and “consisting of”.
- Embodiment 1 Suspending activated carbon in an aqueous liquid to obtain an activated carbon suspension; Heating the activated carbon suspension at 100 ° C. or higher for 20 minutes or more; Stirring and cooling the activated carbon suspension after the heating; A method for purifying hyaluronic acid and / or a salt thereof, comprising a step of contacting a hyaluronic acid solution containing hyaluronic acid and / or a salt thereof and impurities with an activated carbon suspension after stirring and cooling.
- Embodiment 2 Suspending activated carbon in an aqueous liquid to obtain an activated carbon suspension; Heating the activated carbon suspension at 100 ° C. or higher for 20 minutes or more; A method for producing a purification agent for hyaluronic acid and / or a salt thereof, comprising a step of stirring and cooling the activated carbon suspension after the heating.
- Embodiment 3 Suspending activated carbon in an aqueous liquid to obtain an activated carbon suspension; Heating the activated carbon suspension at 100 ° C. or higher for 20 minutes or more; A pretreatment method for activated carbon, comprising a step of stirring and cooling the activated carbon suspension after the heating.
- Embodiment 4 FIG. The method according to any one of Embodiments 1 to 3, wherein in the stirring and cooling step, the cooling completion temperature is 60 ° C. or lower.
- Embodiment 5 The method according to any one of Embodiments 1 to 4, wherein in the step of stirring and cooling, the stirring and cooling is performed at a temperature of 10 to 60 ° C. for 1 hour or longer.
- Embodiment 6 FIG. Embodiment 6. The method according to any one of Embodiments 1 to 5, wherein at least one of the above steps is performed in a clean environment.
- Embodiment 7 FIG. The method according to any one of Embodiments 1 to 6, wherein hyaluronic acid and / or a salt thereof is produced by a fermentation method.
- Embodiment 8 FIG. The method according to any one of the embodiments 1 to 7, wherein the hyaluronic acid and / or salt thereof after purification has an average molecular weight of 3.5 to 7 million Da.
- Embodiment 9 Suspending activated carbon in an aqueous liquid to obtain an activated carbon suspension; Heating the activated carbon suspension at 100 ° C. or higher for 20 minutes or more; A purification agent for hyaluronic acid and / or a salt thereof, comprising activated carbon produced by a method comprising a step of stirring and cooling the activated carbon suspension after the heating.
- the first aspect of the present invention includes a step of suspending activated carbon in an aqueous liquid to obtain an activated carbon suspension, and heating the activated carbon suspension at 100 ° C. or higher for 20 minutes or longer.
- a method of purifying hyaluronic acid comprising: a step of stirring and cooling the activated carbon suspension after heating; and a step of bringing the hyaluronic acid solution containing hyaluronic acid and impurities into contact with the activated carbon suspension after stirring and cooling. It is.
- impurities can be efficiently adsorbed and removed by using activated carbon pretreated in a state suitable for purification of hyaluronic acids.
- the second aspect of the present invention includes a step of suspending activated carbon in an aqueous liquid to obtain an activated carbon suspension, and heating the activated carbon suspension at 100 ° C. or higher for 20 minutes or longer.
- purification agent of hyaluronic acid including the process and the process of stirring and cooling the activated carbon suspension after the heating. According to this production method, a purification agent for hyaluronic acid capable of efficiently adsorbing and removing impurities can be produced by pretreating activated carbon into a state suitable for purification of hyaluronic acid.
- the third aspect of the present invention is a step of suspending activated carbon in an aqueous liquid to obtain an activated carbon suspension, and heating the activated carbon suspension at 100 ° C. or higher for 20 minutes or longer.
- a pretreatment method of activated carbon including a step and a step of stirring and cooling the activated carbon suspension after the heating. According to this pretreatment method, the activated carbon can be pretreated to a state suitable for purification of hyaluronic acids.
- the fourth aspect of the present invention includes a step of suspending activated carbon in an aqueous liquid to obtain an activated carbon suspension, and heating the activated carbon suspension at 100 ° C. or higher for 20 minutes or longer.
- a purification agent for hyaluronic acids comprising activated carbon produced by a method comprising a step and a step of stirring and cooling the activated carbon suspension after the heating.
- the purification method of the above embodiment has a higher impurity adsorption power than the purification method using untreated activated carbon, more effective impurity removal can be performed. .
- the purification method of the above embodiment when used, only high molecular compounds (for example, bacterial cells, proteins, nucleic acids, endotoxins) that can generally be removed by activated carbon as impurities while suppressing the disappearance of hyaluronic acids to a low level.
- high molecular compounds for example, bacterial cells, proteins, nucleic acids, endotoxins
- low molecular weight compounds for example, amino acids, sugars, organic acids
- the purification method of the above aspect can also reduce the decrease in the molecular weight of hyaluronic acids compared to the case where untreated activated carbon is used. It is possible to reduce the decrease in the molecular weight of hyaluronic acids during purification, in particular, the hyaluronic acids having a high molecular weight (for example, an average molecular weight after purification (for example, after filtration following the adsorption treatment) of 3.5 to 7 million Da). Excellent effect in purification.
- a hyaluronic acid solution having a relatively high concentration for example, 1 g / L to 10 g / L, which has conventionally been difficult to process, can be processed efficiently.
- the culture solution itself can be purified (impurities / cells etc. are removed) without performing sterilization treatment, dialysis treatment, purification treatment, etc., and the culture solution itself It also has an excellent effect when separating and purifying hyaluronic acids from sucrose.
- the culture solution By using the culture solution as it is without performing complicated operations such as centrifugation and filtration, it is possible to obtain further efficiency and cost reduction effects.
- the hyaluronic acid concentration of the hyaluronic acid solution when performing the purification method of the above embodiment is not limited to this from the viewpoint of difficulty in handling due to the high solution viscosity and the solubility of hyaluronic acid, 0.1 to 20 g / L is desirable, 0.5 to 15 g / L is more desirable, and 1 to 10 g / L is most desirable.
- the pH of the hyaluronic acid solution to be subjected to the purification method of the above embodiment is not limited to this from the viewpoint of preventing the degradation of hyaluronic acid and preventing the molecular weight from being lowered, but is preferably 3 to 12. ⁇ 9 are most desirable. Furthermore, from the viewpoint of further enhancing the purification (adsorption) effect, the pH is preferably 3.5 or more and / or 7 or less, although not limited thereto.
- the temperature of the hyaluronic acid solution when using the purification method of the above embodiment is not limited to this, but is preferably 0 to 80 ° C. If temperature is 80 degrees C or less, decomposition
- the activated carbon suspension when brought into contact with the hyaluronic acid solution to be purified, it may be suspended once and kept as it is, but it is desirable to continuously suspend and stir. .
- stirring although not limited thereto, stirring for 10 minutes to 1 hour is desirable, and stirring for 20 to 40 minutes is more desirable.
- the ability to remove impurities is improved by heating the activated carbon suspension at 100 ° C. or higher for 20 minutes or longer.
- the temperature is not limited to this, but is more preferably 120 ° C. or higher, and most preferably 121 ° C. or higher.
- the atmospheric pressure during heating is high.
- Such high atmospheric pressure is not limited to this, but is preferably 0.1 MPa or more, and more preferably 0.2 MPa or more.
- the heating time is not limited to this, but is more preferably 30 minutes or more, and most preferably 1 hour or more.
- the heating is preferably performed at 50 to 1000 rpm, and more preferably at 100 to 600 rpm. desirable.
- the heated activated carbon suspension is cooled by continuing stirring.
- the ambient temperature at the time of stirring and cooling is not limited to this, but is preferably 0 ° C. to 80 ° C., more preferably 10 ° C. to 60 ° C., and most preferably 15 to 40 ° C.
- the stirring time is not limited to this, but is preferably 1 hour or more, more preferably 2 hours or more, still more preferably 3 hours or more, and 4 hours or more. Is most desirable. Even if the cooling completion temperature is the same temperature, the effect of reducing the molecular weight of hyaluronic acids when used for purification is greater when stirring for an appropriate stirring time. Further, the cooling completion temperature is desirably lower because of the influence on the molecular weight reduction of hyaluronic acid. Although not limited to this, the cooling completion temperature is desirably 80 ° C. or less, and the cooling completion temperature is more desirably 60 ° C. or less (0 ° C. or more).
- the amount of the activated carbon used in the purification method of the above embodiment is not limited to this, but is desirably 0.5 to 20.0% by weight with respect to 100% by weight of the hyaluronic acid solution. More desirably, it is ⁇ 20.0% by weight. Within these ranges, higher purification (adsorption) action can be expected.
- the raw material for activated carbon is preferably derived from wood, particularly from the viewpoint of impurities that can be a problem when applied to a living body, and its shape is preferably powder from the viewpoint of dispersibility and adsorption efficiency.
- the hyaluronic acid is Streptococcus ex FM-100 (Mikken Kenjo No. 9027) or Streptococcus ex FM-300 (Maiko Kenjo No. 2319). Produced by.
- hyaluronic acid produced by these microorganisms as a purification target, a purified product with high molecular weight hyaluronic acid can be obtained with less impurities, and exhibits an excellent effect particularly when used as a medicine.
- the purification method of the above aspect it is possible to reduce the load of the separation / purification process of hyaluronic acids. Therefore, the purification method according to the above aspect is particularly used at a relatively early stage of the industrial process of production. It is effective.
- the purification method or the like may include another step, or may be a method of producing hyaluronic acid or the like by performing another step or method subsequent to the purification method.
- processes and methods include a step of culturing a hyaluronic acid-producing microbial strain, which is performed simultaneously or separately, a step of producing a culture filtrate from a hyaluronic acid-producing microbial strain culture solution, and centrifuging a solution to be purified.
- Process neutralizing the target liquid, adding salt to the target liquid, microfiltration of the target liquid to be purified, dialysis of the target liquid, adding aromatic adsorption resin to the target liquid to be purified, target
- a step of precipitating hyaluronic acid, a step of crystallizing hyaluronic acid, a step of drying hyaluronic acid and the like can be mentioned.
- the sodium hyaluronate thus obtained was evaluated using the evaluation items and evaluation criteria shown in Table 4.
- the purification conditions and evaluation results are shown in Tables 2 and 3 (Experimental Examples 1 to 17).
Abstract
Description
本明細書における「ヒアルロン酸類」には、遊離のヒアルロン酸、及び、本発明の目的を損なわない範囲で使用可能な任意のヒアルロン酸塩(これに限定されるものではないが、例えば、ナトリウム塩、カリウム塩、カルシウム塩、リチウム塩などの金属塩や、塩酸塩、リン酸塩、クエン酸塩などの酸付加物など)や水和物、それらの混合物が含まれる。ここで、ヒアルロン酸とは、N-アセチル-D-グルコサミンとD-グルクロン酸とが結合した2糖単位がくりかえし連鎖してなる高分子量の多糖類をいい、各種塩は主にグルクロン酸部分が塩の形となったものをいう。ヒアルロン酸は、折り畳み可能な鎖部分と、D-グルクロン酸部分のカルボキシル基の負電荷の相互作用によって、空間に展開しやすく、これにより大量の水と結合してゲルを形成することができる。また、低濃度であっても、分子間力が強いため、比較的高い粘性を有する。このような作用から、例えば、関節の湿潤作用、皮膚の柔軟作用などを有し、生理的にもそれらの役割を担っている。
クリーン環境の一例として、例えば、対象物質が以下のように規制された環境が挙げられる。
本発明は、これに限られるものではないが、例えば、以下の実施態様に関する。
活性炭を水性液中に懸濁させて活性炭懸濁液を得る工程と、
該活性炭懸濁液を100℃以上で20分間以上加熱する工程と、
該加熱後活性炭懸濁液を攪拌冷却する工程と、
ヒアルロン酸及び/又はその塩と不純物とを含むヒアルロン酸類溶液を、該攪拌冷却後活性炭懸濁液と接触させる工程とを含む、ヒアルロン酸及び/又はその塩の精製方法。
活性炭を水性液中に懸濁させて活性炭懸濁液を得る工程と、
該活性炭懸濁液を100℃以上で20分間以上加熱する工程と、
該加熱後活性炭懸濁液を攪拌冷却する工程を含む、ヒアルロン酸及び/又はその塩の精製剤の製造方法。
活性炭を水性液中に懸濁させて活性炭懸濁液を得る工程と、
該活性炭懸濁液を100℃以上で20分間以上加熱する工程と、
該加熱後活性炭懸濁液を攪拌冷却する工程を含む、活性炭の前処理方法。
上記攪拌冷却する工程において、冷却完了温度が60℃以下である、実施態様1ないし3の何れか一態様に記載の方法。
上記攪拌冷却する工程において、攪拌冷却が温度10~60℃で1時間以上行われる、実施態様1ないし4の何れか一態様に記載の方法。
上記工程の少なくとも一つ以上がクリーン環境下で行われる、実施態様1ないし5の何れか一態様に記載の方法。
ヒアルロン酸及び/又はその塩が発酵法で製造されたものである、実施態様1ないし6の何れか一態様に記載の方法。
精製後の上記ヒアルロン酸及び/又はその塩の平均分子量が350万~700万Daである、実施態様1ないし7の何れか一態様に記載の方法。
活性炭を水性液中に懸濁させて活性炭懸濁液を得る工程と、
該活性炭懸濁液を100℃以上で20分間以上加熱する工程と、
該加熱後活性炭懸濁液を攪拌冷却する工程を含む方法により製造された活性炭を含む、ヒアルロン酸及び/又はその塩の精製剤。
Claims (1)
- ヒアルロン酸及び/又はその塩と不純物を含むヒアルロン酸類溶液を、活性炭懸濁液と接触させる工程とを含む、ヒアルロン酸及び/又はその塩の精製方法。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012505379A JP5758878B2 (ja) | 2010-03-17 | 2010-03-17 | ヒアルロン酸の精製方法 |
KR1020127026991A KR101627014B1 (ko) | 2010-03-17 | 2010-03-17 | 히알루론산의 정제 방법 |
PCT/JP2010/054595 WO2011114472A1 (ja) | 2010-03-17 | 2010-03-17 | ヒアルロン酸の精製方法 |
CN201080065525.3A CN102803298B (zh) | 2010-03-17 | 2010-03-17 | 透明质酸的提纯方法 |
TW100109192A TWI549970B (zh) | 2010-03-17 | 2011-03-17 | Purification of hyaluronic acid |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2010/054595 WO2011114472A1 (ja) | 2010-03-17 | 2010-03-17 | ヒアルロン酸の精製方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011114472A1 true WO2011114472A1 (ja) | 2011-09-22 |
Family
ID=44648601
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2010/054595 WO2011114472A1 (ja) | 2010-03-17 | 2010-03-17 | ヒアルロン酸の精製方法 |
Country Status (5)
Country | Link |
---|---|
JP (1) | JP5758878B2 (ja) |
KR (1) | KR101627014B1 (ja) |
CN (1) | CN102803298B (ja) |
TW (1) | TWI549970B (ja) |
WO (1) | WO2011114472A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105899544B (zh) * | 2014-01-14 | 2019-09-20 | 丘比株式会社 | 透明质酸和/或其盐及其制造方法、以及包含该透明质酸和/或其盐的食品、化妆品和药品 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62501471A (ja) * | 1985-01-18 | 1987-06-18 | バイオ−テクノロジ−・ジエネラル・コ−ポレイシヨン | 連鎖球菌の発酵による高分子量ヒアルロン酸ナトリウムの製造方法 |
JPS63270701A (ja) * | 1987-04-30 | 1988-11-08 | Nippon Kayaku Co Ltd | ヒアルロン酸の精製法 |
JP2009242522A (ja) * | 2008-03-31 | 2009-10-22 | Mitsubishi Rayon Co Ltd | ヒアルロン酸およびその塩の製造方法 |
JP2009256463A (ja) * | 2008-04-16 | 2009-11-05 | Mitsubishi Rayon Co Ltd | ヒアルロン酸の精製方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6312293A (ja) | 1986-07-03 | 1988-01-19 | Kyowa Hakko Kogyo Co Ltd | ヒアルロン酸の精製法 |
JP2728542B2 (ja) | 1990-05-07 | 1998-03-18 | 株式会社日立製作所 | 同時2軸延伸装置のリンク過負荷検出装置 |
BRPI0713215A2 (pt) * | 2006-07-06 | 2012-04-17 | Realince Life Sciences Pvt Ltd | processo eficiente de produção e purificação de ácido hialurÈnico de elevado peso molecular e produto resultante |
KR101509139B1 (ko) * | 2006-11-23 | 2015-04-08 | 주식회사 엘지생명과학 | 히알루론산의 정제방법 |
CN101935362B (zh) * | 2009-06-30 | 2012-07-25 | 上海佰加壹医药有限公司 | 预铺助滤剂纯化透明质酸的方法 |
WO2013132506A1 (en) * | 2012-03-07 | 2013-09-12 | Praj Industries Limited | Process for the purification of hyaluronic acid salts (ha) from fermentation broth |
-
2010
- 2010-03-17 KR KR1020127026991A patent/KR101627014B1/ko not_active IP Right Cessation
- 2010-03-17 CN CN201080065525.3A patent/CN102803298B/zh active Active
- 2010-03-17 JP JP2012505379A patent/JP5758878B2/ja active Active
- 2010-03-17 WO PCT/JP2010/054595 patent/WO2011114472A1/ja active Application Filing
-
2011
- 2011-03-17 TW TW100109192A patent/TWI549970B/zh not_active IP Right Cessation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62501471A (ja) * | 1985-01-18 | 1987-06-18 | バイオ−テクノロジ−・ジエネラル・コ−ポレイシヨン | 連鎖球菌の発酵による高分子量ヒアルロン酸ナトリウムの製造方法 |
JPS63270701A (ja) * | 1987-04-30 | 1988-11-08 | Nippon Kayaku Co Ltd | ヒアルロン酸の精製法 |
JP2009242522A (ja) * | 2008-03-31 | 2009-10-22 | Mitsubishi Rayon Co Ltd | ヒアルロン酸およびその塩の製造方法 |
JP2009256463A (ja) * | 2008-04-16 | 2009-11-05 | Mitsubishi Rayon Co Ltd | ヒアルロン酸の精製方法 |
Also Published As
Publication number | Publication date |
---|---|
KR20130056223A (ko) | 2013-05-29 |
TWI549970B (zh) | 2016-09-21 |
TW201139464A (en) | 2011-11-16 |
CN102803298B (zh) | 2015-09-23 |
KR101627014B1 (ko) | 2016-06-03 |
CN102803298A (zh) | 2012-11-28 |
JP5758878B2 (ja) | 2015-08-05 |
JPWO2011114472A1 (ja) | 2013-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2007298454B2 (en) | Efficient process for purification of high molecular weight hyaluronic acid | |
JP7105888B2 (ja) | 低分子ヒアルロン酸又はその塩及びその調製方法 | |
KR20200033223A (ko) | 히알루론산의 정제 공정 | |
CN102242165A (zh) | 一种发酵生产高分子量透明质酸钠的方法及其所用的培养基 | |
KR20080046821A (ko) | 히알루론산의 정제방법 | |
JPH04158796A (ja) | ヒアルロン酸ナトリウム水溶液の製造法 | |
JP2020507666A (ja) | オゾンを用いた多糖類の分解方法 | |
US20120232261A1 (en) | Method for manufacturing low molecular weight hyaluronic acid | |
JP5603926B2 (ja) | ヒアルロン酸の精製方法及び製造方法 | |
TWI504611B (zh) | Hyaluronic acid and / or a salt thereof | |
JP5758878B2 (ja) | ヒアルロン酸の精製方法 | |
KR101858733B1 (ko) | 초저분자량 히알루론산의 제조방법 | |
Srivastav et al. | Biotechnological production and purification of hyaluronic acid from Streptococcus zooepidemicus | |
AU2011369262A1 (en) | Shark-like chondroitin sulphate and process for the preparation thereof | |
JP2007063400A (ja) | アオヤギ由来のコンドロイチン硫酸 | |
KR20110056346A (ko) | 고순도의 의료용 히아루론산의 제조 방법 | |
JP2938880B2 (ja) | ヒアルロン酸の精製法 | |
JP2009284826A (ja) | ヒアルロン酸の製造方法 | |
Kanala et al. | Microbial production of high purity hyaluronic acid from Streptococcus zooepidemicus | |
Kanala et al. | Efficient recovery of hyaluronic acid from highly viscous culture broth | |
JPH01313503A (ja) | ヒアルロン酸の精製法 | |
BR102016030092A2 (pt) | processo de produção de exopolissacarídeo a partir de mortierella ssp por fermentação submersa utilizando meio de cultura de baixo custo | |
JP2002262900A (ja) | グリコサミノグリカン二糖の製造方法。 | |
JPH04234983A (ja) | デキストリンデキストラナーゼ及びその生産方法 | |
AU2013273729A1 (en) | Efficient process for purification of high molecular weight hyaluronic acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080065525.3 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10847887 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012505379 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20127026991 Country of ref document: KR Kind code of ref document: A |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10847887 Country of ref document: EP Kind code of ref document: A1 |